DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer

Free circulating DNA, which is thought to be derived from the primary tumour, can be detected in the blood of patients with cancer. Detection of genetic and epigenetic alteration in this tumour DNA offers a potential source of development of prognostic and predictive biomarkers for cancer. One such...

Full description

Bibliographic Details
Main Authors:	Ruth E Board, Lucy Knight, Alastair Greystoke, Fiona H Blackhall, Andrew Hughes, Caroline Dive5, Malcolm Ranson
Format:	Article
Language:	English
Published:	SAGE Publishing 2007-01-01
Series:	Biomarker Insights
Subjects:	DNA methylation biomarker circulating tumour DNA MSP MethyLight
Online Access:	http://la-press.com/article.php?article_id=500

Similar Items

Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers
by: Nam-Yun Cho, et al.
Published: (2020-12-01)

Combined Analysis of COX-2 and p53 Expressions Reveals Synergistic Inverse Correlations with Microsatellite Instability and CpG Island Methylator Phenotype in Colorectal Cancer
by: Shuji Ogino, et al.
Published: (2006-06-01)

F-box protein 43 promoter methylation as a novel biomarker for hepatitis B virus-associated hepatocellular carcinoma
by: Ying Zhang, et al.
Published: (2023-11-01)

SOCS1 methylation level is associated with prognosis in patients with acute-on-chronic hepatitis B liver failure
by: Feng Li, et al.
Published: (2023-05-01)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
by: Joanna Kapeleris, et al.
Published: (2022-03-01)

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer
by: Lavanya Sivapalan, et al.
Published: (2022-04-01)

Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma
by: Xiaomin Huang, et al.
Published: (2023-08-01)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
by: Ashleigh C. McEvoy, et al.
Published: (2018-07-01)

Potential of circulating tumour DNA as a biomarker in liquid biopsy
by: Dimitar Dimitrov, et al.
Published: (2023-11-01)

The Prognostic Utility of <i>KRAS</i> Mutations in Tissue and Circulating Tumour DNA in Colorectal Cancer Patients
by: Joel Petit, et al.
Published: (2024-01-01)

Landscape of circulating tumour DNA in metastatic breast cancer
by: Andrew A. Davis, et al.
Published: (2020-08-01)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
by: Jan M. van Rees, et al.
Published: (2023-01-01)

Predicting tumour content of liquid biopsies from cell-free DNA
by: Mathias Cardner, et al.
Published: (2023-09-01)

Promoter hypermethylation of RARB and GSTP1 genes in plasma cell‐free DNA as breast cancer biomarkers in Peruvian women
by: Pierina Danos, et al.
Published: (2023-12-01)

Ultra-Low DNA Input into Whole Genome Methylation Assays and Detection of Oncogenic Methylation and Copy Number Variants in Circulating Tumour DNA
by: Celina Whalley, et al.
Published: (2021-02-01)

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
by: Lissa Wullaert, et al.
Published: (2023-10-01)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
by: Joanna Kapeleris, et al.
Published: (2022-07-01)

Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer
by: Jedrzej J. Jaworski, et al.
Published: (2020-12-01)

Comparison of Circulating Tumour DNA and Extracellular Vesicle DNA by Low-Pass Whole-Genome Sequencing Reveals Molecular Drivers of Disease in a Breast Cancer Patient
by: Olivia Ruhen, et al.
Published: (2020-12-01)

Circulating cell-free DNA (cfDNA) in patients with medullary thyroid carcinoma is characterized by specific fragmentation and methylation changes with diagnostic value
by: Anna Citarella, et al.
Published: (2023-09-01)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
by: Huanwen Wu, et al.
Published: (2022-11-01)

Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
by: Matthew Loft, et al.
Published: (2019-07-01)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients
by: Guillaume Herbreteau, et al.
Published: (2020-07-01)

Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer
by: Ricardo Roque, et al.
Published: (2024-01-01)

Liquid Biopsies: Emerging role and clinical applications in solid tumours
by: Sandeep Sisodiya, et al.
Published: (2023-09-01)

DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients
by: Sridurga Mithraprabhu, et al.
Published: (2019-06-01)

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancerResearch in context
by: Andrew A. Davis, et al.
Published: (2022-12-01)

Application of circulating tumour DNA in terms of prognosis prediction in Chinese follicular lymphoma patients
by: Mengjing Zhao, et al.
Published: (2023-04-01)

Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives
by: Vanathi Perumal, et al.
Published: (2019-03-01)

Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study
by: Yat Hang To, et al.
Published: (2023-10-01)

Comparing single‐target and multitarget approaches for postoperative circulating tumour DNA detection in stage II–III colorectal cancer patients
by: Tenna Vesterman Henriksen, et al.
Published: (2022-10-01)

Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases
by: Karen Bolhuis, et al.
Published: (2021-08-01)

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond <i>BRAF</i> Mutant Detection
by: Gabriela Marsavela, et al.
Published: (2020-12-01)

Erratum: Application of circulating tumour DNA in terms of prognosis prediction in chinese follicular lymphoma patients
by: Frontiers Production Office
Published: (2023-06-01)

From planned neck dissection to PET response to circulating tumour DNA: changes in post‐treatment assessment of HPV‐driven oropharyngeal cancer†
by: Carl M. Post, et al.
Published: (2024-03-01)

Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer
by: Gillian Vandekerkhove, Alexander Wyatt
Published: (2020-10-01)

Liquid Biopsy in Small Cell Lung Cancer—A Route to Improved Clinical Care?
by: Matt Church, et al.
Published: (2020-12-01)

Whole‐genome bisulfite sequencing analysis of circulating tumour DNA for the detection and molecular classification of cancer
by: Yibo Gao, et al.
Published: (2022-08-01)

Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma
by: Michael Davidson, et al.
Published: (2019-05-01)

Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
by: Daan C. L. Vessies, et al.
Published: (2022-07-01)